Hims & Hers Health (NYSE:HIMS) Insider Sells $830,410.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $32.77 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a market capitalization of $7.59 billion, a P/E ratio of -364.17, a price-to-earnings-growth ratio of 46.74 and a beta of 2.37. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The company’s 50-day moving average is $27.75 and its 200 day moving average is $26.41.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health in the first quarter valued at about $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares in the last quarter. Amundi lifted its stake in Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System lifted its stake in Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after acquiring an additional 29,471 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of several research analyst reports. UBS Group set a $23.00 price objective on Hims & Hers Health in a research report on Friday, May 22nd. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Finally, Citigroup raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $29.37.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.